TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04628884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose
Description: Conventional dose used to calculated the protamine dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing according residual heparin
Description: In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
Study: NCT00878852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment Plus Contingency Management Program
Description: Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
Study: NCT00668278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of laryngeal mask airway (AuraOnce mask)
Description: Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
Study: NCT04513262

Intervention type: PROCEDURE
Intervention: mechanical ventilation during video-assisted surgery
Description: observed variation of ventilatory parameters during video-assisted surgery
Study: NCT03165318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field Therapy
Description: Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance.
Study: NCT02323763

Intervention type: OTHER
Intervention: fMRI Scanning
Description: Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
Study: NCT02673619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
Study: NCT02274168

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional RF catheter ablation
Description: RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational RF Catheter Ablation using ICD-EG information
Description: RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
Study: NCT02247908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon General's Warning
Description: Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~1. SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~2. SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~3. SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~4. SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphic Warning
Description: Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~1. Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~2. Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~3. Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~4. Text: WARNING: Smoking can kill you. Image: Woman dying from cancer.
Study: NCT03144804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
Study: NCT01540383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive integrative aphasia therapy
Description: Intensive language therapy (3 weeks, 5 days/week, \>=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control group
Description: Control group starts intensive language therapy after a 3-week waiting period.
Study: NCT03384914

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC1 Vaccine
Description: Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: WOKVAC Vaccine
Description: Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month).
Study: NCT02632760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: treatment for Iron deficient anaemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo - no active drug
Study: NCT04712825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioural therapy
Description: Cognitive-behavioural therapy sessions during 6 weeks of treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HypnoVR® device
Description: HypnoVR® sessions during 6 weeks of treatment
Study: NCT01153802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin
Description: This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study.
Study: NCT02952391

Intervention type: OTHER
Intervention: [18F] FEOBV PET scan
Description: Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol

Intervention type: OTHER
Intervention: [18F] FEOBV PET scan
Description: Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol
Study: NCT03136419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG
Description: Lactobacillus casei DG probiotic supplementation for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation for 8 weeks
Study: NCT03765775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
Study: NCT00509665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
Study: NCT01444651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 20 mg Tadalafil taken once a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken by mouth once a day for 3 months
Study: NCT06140472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phoenix
Description: Specific individualized nurse follow-up using the PHOENIX application.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Journal de bord
Description: Regular nursing follow-up, with the use of an electronic journal.
Study: NCT02774902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets
Study: NCT00152698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irbesartan
Study: NCT03348865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fertility Life Counselling Aid (FeLiCiA)
Description: The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
Study: NCT03874325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Description: Participants will self administer 1 mg anastrozole by mouth daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Description: Participants will self administer 1 mg anastrozole by mouth daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane 25 MG
Description: Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane 25 MG
Description: Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
Study: NCT03707132

Intervention type: PROCEDURE
Intervention: Tourniquet: Folley catheter in the low segment of the uterus
Study: NCT04436237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality foot placement training
Description: The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality foot placement training
Description: The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
Study: NCT00754143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FG-3019
Description: Placebo every 2 weeks IV for all infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 5 mg/kg every 2 weeks IV for all infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
Study: NCT01016964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb 2009 model 12 beam
Description: HairMax LaserComb

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Device
Study: NCT03837314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioinduction Picostim Deep Brain Stimulation system
Description: Neurostimulation of the subthalamic nucleus region.
Study: NCT01920594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
Study: NCT03811639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency ablation
Description: Ablation for atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Ablation for atrial fibrillation
Study: NCT02870569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib 200mg
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donafenib 300mg
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
Study: NCT03903874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep south Interactive voice response system supported Active Lifestyle (DIAL)
Description: 12 months of automated telephone physical activity counseling with community health worker support
Study: NCT00256334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
Study: NCT02460497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Study: NCT00597077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate vs rhythm control strategies for atrial fibrillation
Description: Rate vs rhythm control strategies for atrial fibrillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate vs rhythm control strategies in atrial fibrillation
Description: rate vs rhythm control strategies in atrial fibrillation
Study: NCT02221986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation
Study: NCT03305068

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Study: NCT02106754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention with Coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT00420017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Intravenous amiodarone continuous infusion x 4 days

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No amiodarone
Study: NCT03868969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Oral Suspension
Description: Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
Study: NCT02706301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Coping Skills Training (CST)
Study: NCT03786978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care
Description: Patients receive a structured pharmaceutical care from one year after basal hospital discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Patient received a single phone call 30 days after basal hospital discharge.
Study: NCT05794113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app - CanImmunize
Description: Using a mobile app

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Web based notification
Description: Using a web-based version of a survey
Study: NCT01449877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
Study: NCT02872077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Study: NCT02619968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: experimental group
Description: Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.